TY - JOUR
T1 - Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years
T2 - A study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
AU - Necchi, Andrea
AU - Miceli, Rosalba
AU - Bregni, Marco
AU - Bokemeyer, C.
AU - Berger, L. A.
AU - Oechsle, K.
AU - Schumacher, K.
AU - Kanfer, E.
AU - Bourhis, J. H.
AU - Massard, C.
AU - Laszlo, Daniele
AU - Montoro Gomez, Juan Bautista
AU - Fléchon, A.
AU - Arpaci, F.
AU - Secondino, Simona
AU - Wuchter, P.
AU - Dreger, P.
AU - Crysandt, M.
AU - Worel, N.
AU - Kruger, W.
AU - Ringhoffer, Mark
AU - Unal, A.
AU - Nagler, Arnon
AU - Campos, A.
AU - Wahlin, A.
AU - Michieli, Mariagrazia
AU - Sucak, G.
AU - Donnini, I.
AU - Schots, R.
AU - Ifrah, Norbert
AU - Badoglio, Manuela
AU - Martino, M.
AU - Raggi, D.
AU - Giannatempo, Patrizia
AU - Rosti, G.
AU - Pedrazzoli, Paolo
AU - Lanza, F.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced germ cell tumors. Twenty European Society for Blood and Marrow Transplantation centers contributed data on patients treated between 2002 and 2012. Paclitaxel used in either prior lines of therapy or in induction-mobilization regimens was considered. Multivariable Cox analyses of prespecified factors were undertaken on PFS and overall survival (OS). As of October 2013, data for 324 patients had been contributed to this study. One hundred and ninety-two patients (59.3%) had received paclitaxel. Sixty-one patients (19%) had a progression to induction chemotherapy, 234 (72%) a response (29 (9%) missing or granulocyte colony-stimulating factor without chemotherapy). Both progression to induction chemotherapy and prior paclitaxel were significantly associated with shorter OS univariably (P
AB - Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced germ cell tumors. Twenty European Society for Blood and Marrow Transplantation centers contributed data on patients treated between 2002 and 2012. Paclitaxel used in either prior lines of therapy or in induction-mobilization regimens was considered. Multivariable Cox analyses of prespecified factors were undertaken on PFS and overall survival (OS). As of October 2013, data for 324 patients had been contributed to this study. One hundred and ninety-two patients (59.3%) had received paclitaxel. Sixty-one patients (19%) had a progression to induction chemotherapy, 234 (72%) a response (29 (9%) missing or granulocyte colony-stimulating factor without chemotherapy). Both progression to induction chemotherapy and prior paclitaxel were significantly associated with shorter OS univariably (P
UR - http://www.scopus.com/inward/record.url?scp=84959514192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959514192&partnerID=8YFLogxK
U2 - 10.1038/bmt.2015.300
DO - 10.1038/bmt.2015.300
M3 - Article
SN - 0268-3369
VL - 51
SP - 384
EP - 390
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 3
ER -